Assessment of Oral and Nasal Breathing With Sensors Analyzing Algorithm
NCT ID: NCT05869071
Last Updated: 2023-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2023-05-23
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study for the Application of Low Power External Bioelectronic Devices in the Diagnosis of Bronchial Asthma.
NCT06836375
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
NCT06858748
A Retrospective Study to Evaluate the Predictability of Abnormal Arterial Blood Gas Measurements Through Novel Observations of Continuous Trends in Electronically Measured Respiratory Rate in a Mixed Cohort of Respiratory Compromised Patients
NCT05384314
Evaluation of Novel Lung Function Parameters in Patients With Bronchial Asthma
NCT03820427
FIBRotic Interstitial Lung Disease and Nocturnal OXygen
NCT04586946
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy volunteers
Participants with no chronic disease and no acute symptoms
Sensor analyzing software (own development)
A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
Body plethysmograph
Body plethysmograph measures specific airway resistance
Patients with Allergic rhinitis or Nasal Polyps
Participants with allergic rhinitis or nasal polyps
Sensor analyzing software (own development)
A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
Body plethysmograph
Body plethysmograph measures specific airway resistance
Patients with asthma
Participants with asthma
Sensor analyzing software (own development)
A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
Body plethysmograph
Body plethysmograph measures specific airway resistance
Patients with COPD
Participants with Chronic Obstructive Pulmonary Disease
Sensor analyzing software (own development)
A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
Body plethysmograph
Body plethysmograph measures specific airway resistance
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sensor analyzing software (own development)
A software the research group developed. Analyzes acoustic and accelerator signals to measure airway obstruction.
Body plethysmograph
Body plethysmograph measures specific airway resistance
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 5 patients with allergic rhinitis or nasal polyps (diagnosis of allergic rhinitis confirmed by a PRICK test or specific Ig E antibody tests and Nasal polyposis diagnosed by an ENT specialist, with endoscopy)
* 5 patients with asthma (diagnosis of asthma based on peak expiratory flow (PEF) monitoring, spirometry, or other appropriate objective measurement methods performed by a pulmonologist
* 5 patients with Chronic Obstructive Pumonary Disease (diagnosis of COPD based on spirometry (post-bronchodilator Forced Expiratory Volume/ Forced Vital Capacity (FEV1/FVC) ratio below 0.70)
Exclusion Criteria
* History of surgical procedures in the chest, larynx, throat (excluding tonsillectomy), or nasal area.
* Recent illnesses or surgeries that pose a risk to the patient or prevent proper measurement (common contraindications for spirometry):
* Recent (\<1 month) myocardial infarction.
* Severe coronary artery disease with easily triggered symptoms.
* Cerebral artery aneurysm.
* Recent brain (\<4 weeks) or eye (\<1 week) surgery.
* Severe cardiac arrhythmias.
* Pulmonary tuberculosis.
* Pneumothorax
* Immediate postoperative period of lung surgery (\<1 day).
* Dementia or confusion.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oulu University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Olli-Pekka Alho, MD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olli-Pekka Alho, Prof
Role: PRINCIPAL_INVESTIGATOR
University of Oulu, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oulu University Hospital
Oulu, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
126/2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.